Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2014 Nov 13.
Published in final edited form as: J Am Chem Soc. 2013 Oct 31;135(45):16758–16761. doi: 10.1021/ja407438p

A 2.8 Å Fe-Fe Separation in the Fe2III/IV Intermediate (X) from Escherichia coli Ribonucleotide Reductase

Laura M K Dassama 1,2,&, Alexey Silakov 1, Courtney M Krest 1,#, Julio C Calixto 1, Carsten Krebs 1,2,*, J Martin Bollinger Jr 1,2,*, Michael T Green 1,*
PMCID: PMC4209742  NIHMSID: NIHMS536987  PMID: 24094084

Abstract

A class Ia ribonucleotide reductase (RNR) employs a µ-oxo-Fe2III/III/tyrosyl radical cofactor in its β subunit to oxidize a cysteine residue ~ 35 Å away in its α subunit; the resultant cysteine radical initiates substrate reduction. During self-assembly of the Escherichia coli RNR-β cofactor, reaction of the protein’s Fe2II/II complex with O2 results in accumulation of an Fe2III/IV cluster, termed X, which oxidizes the adjacent tyrosine (Y) 122 to the radical (Y122•) as the cluster is converted to the µ-oxo-Fe2III/III product. As the first high-valent non-heme-iron enzyme complex to be identified and the key activating intermediate of class Ia RNRs, X has been the focus of intensive efforts to determine its structure. Initial characterization by extended X-ray absorption fine structure (EXAFS) spectroscopy yielded a 2.5 Å Fe-Fe separation (dFe-Fe), which was interpreted to imply the presence of three single-atom bridges (O2−, HO, and/or µ-1,1-carboxylates). This short dFe-Fe has been irreconcilable with computational and synthetic models, which all have dFe-Fe ≥ 2.7 Å. To resolve this conundrum, we revisited the EXAFS characterization of X. Assuming that samples containing increased concentrations of the intermediate would yield EXAFS data of improved quality, we applied our recently developed method of generating O2 in situ from chlorite using the enzyme chlorite dismutase to prepare X at ~ 2.0 mM, > 2.5 times the concentration realized in the previous EXAFS study. The measured dFe-Fe of 2.78 Å is fully consistent with computational models containing a (µ-oxo)2-Fe2III/IV core. The correction of dFe–Fe brings the experimental data and computational models into full conformity and thus informs analysis of the mechanism by which X generates Y122•.


Ribonucleotide reductases (RNRs) catalyze the conversion of ribonucleotides to deoxyribonucleotides, thus providing all organisms with precursors for the de novo synthesis and repair of DNA.1,2 All RNRs identified to date utilize a free-radical mechanism. A transient cysteine thiyl radical (C•),3 generated in situ in the first step of the reaction, abstracts a hydrogen atom from the 3'-position of the bound nucleotide. The mechanism by which the C• is generated in each turnover is the basis for the division of RNRs into classes I-III.1,2

A class Ia RNR, such as the prototypical orthologue from aerobically-growing Escherichia coli (Ec), functions as a 1:1 complex of homodimeric subunits, α2 and β2. The α subunit binds substrates and allosteric effectors and contains the C residue (C439 in Ec RNR) that is oxidized to the C•, whereas the β subunit self-assembles a µ-oxo-Fe2III/III/tyrosyl radical cofactor that functions to generate the C• reversibly in each catalytic cycle.4,5 The functional cofactor is produced by reaction of the Fe2II/II complex of β with O2.6 Addition of O2 yields a µ-peroxo-Fe2III/III (P) complex79 that is reduced upon cleavage of the O−O bond of the peroxo moiety. In the Ec β reaction, the O–O-cleavage step results in the one-electron oxidation of the solvent-accessible W48 to a cation radical (W48+•)10 with concomitant formation of an Fe2III/IV form of the diiron cluster termed cluster X.11 The Ec W48+• can be reduced in vitro by small-molecule reductants including ascorbate and thiols,10 but it is possible that an accessory protein serves as the reductant in vivo.12 The decay of the W48+• leaves X to oxidize the nearby Y122 residue to the stable Y122•. In the process, X is reduced to the µ-oxo-Fe2III/III cluster of the active β subunit.6,11,13 The Y• is strictly conserved among all class Ia and Ib RNRs and is absolutely required for their activity.1,4,14

The importance of X to the function of class Ia RNRs (which include the Homo sapiens orthologue) has made it a prime target for structural characterization. For Ec RNR, the rapid rate at which X decays (~ 1 s−1 in the wild type β; 0.2 s−1 in the Y122F variant at 5 °C11,13) has thus far prevented characterization by X-ray crystallography. Instead, the freeze-quench technique has been used to trap the intermediate, and it has then been characterized by a variety of spectroscopic methods.13,1521 Density functional theory (DFT) calculations have afforded models for its diiron core, and these models have been evaluated for consistency with the spectroscopic data.2226 This approach, now commonplace in investigations of reactive metalloenzyme intermediates,27 has thus far failed to forge a consensus regarding the structure of X. The primary reason is that the short Fe-Fe separation (dFe-Fe ~ 2.5 Å)19 of the intermediate determined by extended X-ray absorption fine structure (EXAFS) spectroscopy seemingly requires a structure with three single-atom bridges provided by some combination of the protein carboxylate ligands and O2/solvent-derived hydr(oxo) ligands. Such a structure has been disfavored in computational studies on energetic grounds. Indeed, structures favored in these studies have values of dFe-Fe ≥ 2.7 Å and no more than two single-atom oxygen bridges.16,2325 Furthermore, none of the available synthetic models for X has had such a short dFe-Fe.2830 Additionally, structural metrics determined by EXAFS for a MnIV/FeIII homolog of X in the RNR from Chlamydia trachomatis have agreed with those derived by DFT, 31 indicating that current DFT methods are capable of accurately predicting the structures of such enzyme-bound dinuclear complexes.

We sought to resolve the conundrum concerning the structure of X by revisiting the irreconcilably short dFe-Fe determined in the initial EXAFS study. The kinetics of the activation reaction preclude trapping of X in pure form, with a maximum fraction of ~ 0.7 having been achieved in published studies. The challenging kinetics had conspired with the poor solubility of O2 in aqueous solutions (< 2 mM at 1 atm) to limit the concentration of X that could be trapped to < 0.8 mM. Recent technological advancements now permit accumulation of O2-derived intermediates at concentrations exceeding 2 mM,32 and we reasoned that the ability to trap X at elevated concentrations might yield samples of higher quality to permit the re-characterization of the intermediate by EXAFS.

Samples for this study were prepared by the method of generating O2 in situ from chlorite (ClO2) with the enzyme chlorite dismutase (Cld). A reactant solution containing a high concentration of the pre-formed Fe2II/II complex of Ec RNR-β-Y122F and a catalytic concentration (12.5 µM) of Cld was mixed with 0.25 equivalent volumes of a second reactant solution containing ClO2−, and the reaction was freeze-quenched after 0.3 s (at 5 °C). The 4.2-K/53-mT Mössbauer spectra of the freeze-quenched samples reveal the presence of ~ 65% X, comparable to the maximum fraction obtained in the previous EXAFS study, along with ~ 18 % unreacted FeII species and ~ 18 % of µ-oxo-Fe2III/III product cluster (Figures S1-S3 of the Supporting Information). This fraction of X corresponds to 2.0 mM, more than 2.5 times the maximum concentration attained in the previous EXAFS study.

The X-ray absorption near-edge structure (XANES) spectra (Figure S4) show a higher K-edge absorption energy (the energy at which the 1s-core electron is ejected) for samples containing X than for the samples of the unreacted Fe2II/II-β starting material. However, the edge of the X samples lies at a lower energy than for samples of the µ-oxo-Fe2III/III product. This phenomenon, also observed by Riggs-Gelasco et al.,19 may result from the contribution of the unreacted Fe2II/II component in the freeze-quenched samples of X. Alternatively, the skewing of the edge energy to a lower value may be a feature inherent to X that remains to be explained theoretically.

Fe K-edge EXAFS data over k = 0.3 – 14 Å−1 (for samples containing the Fe2II/II reactant complex and the µ-oxo-Fe2III/III product state) and k = 0.3 – 16 Å−1 (for samples containing X) are shown in Figure 1, along with fits to the raw data based on the parameters given in Tables 1 and S1-S3. The EXAFS data of the Fe2II/II reactant complex (Figure 1A, left panel) are best fit with a model that contains a total coordination number of four oxygen/nitrogen (O/N) ligands per Fe. This value is consistent with the crystal structure of that enzyme form.33 There is no evidence for an Fe-Fe scatterer in the Fourier transform (FT) of the EXAFS (Figure 1A, right panel), presumably because dFe-Fe is too large (~ 3.8 Å33) in this form of the cluster. The EXAFS data of the µ-oxo-Fe2III/III product cluster (Figure 1B, left panel) can be fit with a model that contains six O/N ligands per Fe.34 Furthermore, the FT of the EXAFS data exhibits a prominent Fe scattering interaction at R = 3.2 Å (Figure 1B, right panel), a value that is also consistent with the reported dFe-Fe of this form.35,36

Figure 1.

Figure 1

Fe K-edge EXAFS data (left panel) and their Fourier transforms (right panel) for samples containing the Fe2II/II reactant complex (A), the µ-oxo-Fe2III/III product (B) and X (C, D). Fit parameters are provided in Tables 1, S1, S2, and S3.

Table 1.

Fe K-edge EXAFS (k = 0.3 − 16 Å−1) fitting results of samples containing X for which the fit model includes two discernable Fe−Fe interactions. Occupancies were fixed during the fit, but distances, Debye-Waller factors, and the threshold energy shift were allowed to vary

Scatterer Type N R σ2
Fe−O/N 5 2.02 0.0097
Fe−O 0.65 1.75 0.0020
Fe−C 3 2.97 0.0046
Fe−C 1 3.24 0.0060
Fe−Fe 0.65 2.79 0.0033
Fe−Fe* 0.18 3.22 0.0043

F 0.366
E0 −11.067
Resolution 0.099 Å

N: occupancy; R: distance (Å); σ2: Debye-Waller factor (Å2); E0: threshold energy shift (eV); F: fit error.

*

Parameters for this scattering interaction were constrained to the values obtained from fits of the diferric EXAFS

The EXAFS data for the samples containing X (Figure 1C, left panel) can be fit by a model with 3 O/N at 2.01 Å, 2 O/N at 2.11 Å, and 0.65 O at 1.75 Å per Fe. This fit also includes two Fe-Fe scattering interactions: 0.65 Fe at 2.78 Å, and 0.18 Fe at 3.22 Å (Table S3). The occupancies of the two Fe-Fe scattering interactions account for the heterogeneity of the sample, specifically the fractions of X and µ-oxo-Fe2III/III cluster determined from the Mössbauer data. The contribution to the Fe-Fe scattering interactions in the EXAFS data from the ~ 18% Fe2II/II component in the samples is not obvious and is not accounted for in the analysis. The Fe-O/N interaction at 1.75 Å is likely to arise from an oxo bridge, and the occupancy of 0.65 is consistent with the presence of two such µ-oxo interactions in an asymmetric di-µ-oxo-Fe2 core (see Table S3 for additional fitting results).

The agreement between the fit and the data at R ≥ ~3.0 Å can be improved through the inclusion of additional non-nearest-neighbor scattering interactions. Examination of the crystal structures of the reactant and product complexes reveals the presence of carbon atoms from the bridging and terminal carboxylates and histidines that could contribute to scattering interactions at ~ 3.0 and ~ 3.2 Å. In the crystal structure of the Fe2III/III product state (1RIB), there are a total of 6 carbons (three per Fe) at ~ 3.0 Å and 2 carbons (one per Fe) at 3.2 Å away from the Fe ions.34 Assuming that these atoms might also be present at similar distances in the samples containing X, we included three Fe-C scattering interactions at 3.0 Å and one at 3.2 Å into the fit model. Their inclusion significantly improves the agreement between the fit and the data (Figure 1D; parameters provided in Table 1). It is unclear why these interactions would be required for fits of X but not the diferric EXAFS. It is possible that the high-valent X contains a tighter core, making these scattering interactions pronounced. Irrespective of the origin of the additional interactions, the dominant scattering interaction at ~2.8 Å can be assigned to an Fe scatterer, and there is no evidence for an interaction at the previously reported dFe-Fe of ~ 2.5 Å.

To determine the structure of the diiron core of X and rationalize the 2.8 Å dFe-Fe, we generated a series of structural models by broken-symmetry DFT methods, following previous work by Noodleman and coworkers2226 (see Supporting Information for a more detailed description). The models were derived from the X-ray crystallographic data (1RIB) of Ec β by modifying the ligation. Two main candidates were examined in detail, a di-(µ-oxo)-(µ-1,3-carboxylato) core structure and a (µ-oxo)(µ-hydroxo)(µ-1,3-carboxylato) structure (Figure 2). The di-(µ-oxo) model has distance parameters that closely match the experimentally determined values, including, most notably, the dFe-Fe of 2.8 Å (Figure 2).

Figure 2.

Figure 2

Structural models for the Fe2III/IV core of X derived from broken-symmetry DFT calculations. Left: (µ-oxo)2 core; Right: (µ-oxo)(µ-hydroxo) core.

It is noteworthy that the DFT calculations imply that protonation of one of the µ-oxo bridges should result in an elongation of the Fe-Fe separation to ~ 3.0 Å, the distance at which a minor scatterer is detectable in the data. The results of magnetic circular dichroism studies on X suggested a model in which one of the bridging oxo groups is protonated.16 The inclusion of an Fe scatterer at ~3.0 Å (in lieu of additional C scatters at 3.0 and 3.2 Å) also improves the fit in this region. However, such a structure has remained inconsistent with data from 2H-electron-nuclear double resonance experiments, which do not detect a bridging hydron.18,20,21

The effect of including the essential Y122 that is oxidized by X in the DFT calculations was also evaluated (see Supporting Information for a more detailed description of the computational methodology). Y122 forms a hydrogen bond to aspartate 84, which ligates Fe1 of the Fe−Fe cluster. Thus, its presence provides a proton transfer pathway by which one of the µ-oxo bridges in X might be protonated, thereby altering the core structure of the intermediate. The results of our DFT calculations, similar to those of Noodleman and co-workers, show that the presence of Y122 has a minor effect on the optimized geometries, resulting in only a slight increase (~ 0.02 Å) in dFe−Fe (Table S9). Thus, it seems unlikely that the structure of X in the β-Y122F variant could be significantly different from that formed in the wild-type protein.

In an effort to understand the basis for the discrepancy between the dFe-Fe of 2.8 Å determined here and the previously reported distance of 2.5 Å, we considered that third-generation synchrotron technology and the increased (2.5 ×) concentration of X (obtained through the use of Cld and ClO2) could result in a critical increase in signal-to-noise ratio. Interestingly, this was not the case. The data from both studies have effectively the same signal-to-noise ratio. We also considered that the increased resolution provided by the extended k-range of our measurements might be critical to the observation of the 2.8 Å Fe-Fe distance. Whereas the data analyzed in the previous study were limited to k = 2 – 12.6 Å−1, the data reported here were fit from k = 0.3 – 16 Å−1. To evaluate whether this difference might be a plausible explanation for the discrepant results, we examined FTs of unfiltered EXAFS data with cutoffs at k = 11, 12, 13, 14, 15, and 16 Å−1. Figure 3 shows that the intensity of the 2.8 Å peak does decrease with k, becoming a shoulder when kmax = 11.0 Å−1. However, fits over five of the six k ranges listed in Figure 3 yield an Fe-Fe distance of 2.8 Å. (Fits of the shortest range, k=0–11 Å−1, yield an Fe-Fe distance of 2.37 Å, with a large Debye-Waller factor of 0.01.) In no case does truncation of our data lead to the assignment of a 2.5 Å Fe-Fe scattering interaction. It appears then that the data reported herein and the previous study are inherently different, suggesting that they were obtained from inherently different samples (i.e., not from the same species). To illustrate this point, we overlay the EXAFS obtained from both studies in Figure S8.

Figure 3.

Figure 3

FT of EXAFS data of samples containing X plotted with different cutoffs of the k-range. The dashed line is drawn at the middle of the ~ 2.8 Å peak. Overlaid in red is the FT resulting from the fit reported in Table 1.

This re-examination of the structure of X and subsequent upward adjustment of its dFe−Fe calls into question the short dFe−Fes reported for other O2-derived diiron intermediate complexes. For example, the high-valent Fe2IV/IV complex, Q, that accumulates during the conversion of methane to methanol by the soluble methane monooxygenase from Methylosinus trichosporium OB3b was characterized by EXAFS, and the measured dFe−Fe of 2.46 Å led to the proposal of a [(µ-oxo)2Fe2] "diamond core" structure.37 Subsequently, EXAFS characterization of the µ-peroxo-Fe2III/III complexes that accumulate in the reactions of M ferritin from frog38 and the D84E/W48A variant of Ec RNR-β39 led to reports of similar values of dFe−Fe (~ 2.5 Å) even in these mid-valent complexes. In general, the structures dictated by these surprisingly short Fe-Fe separations have been irreconcilable with synthetic and computational models, which predict dFe−Fes of ~ 2.7 Å for Q and > 3.0 Å for the µ-peroxo-Fe2III/III complexes.4043 Re-examination of these other complexes and re-determination of their Fe-Fe separations would seem to be warranted.

Supplementary Material

1_si_001

Scheme 1.

Scheme 1

Schematic description of the activation Ec class Ia RNR. Intermediate X is the precursor to the active Fe2III/III/Y• cofactor.

ACKNOWLEDGMENT

Portions of this research were carried out at the Stanford Synchrotron Radiation Lightsource, a Directorate of SLAC National Accelerator Laboratory and an Office of Science User Facility operated for the U.S. Department of Energy Office of Science by Stanford University. The SSRL Structural Molecular Biology Program is supported by the DOE Office of Biological and Environmental Research, and by the National Institutes of Health, National Institute of General Medical Sciences (including P41GM103393). The authors thank beam line scientists Matthew J. Latimer and Erik J. Nelson for assistance during data acquisition.

Funding Sources

This work was supported by the National Institutes of Health (GM-55365 to JMB, CK, and MTG) and an Alfred P. Sloan Minority Ph.D. fellowship to LMKD.

ABBREVIATIONS

RNR

ribonucleotide reductase

Ec

Escherichia coli

DFT

Density Functional Theory

EXAFS

extended X-ray absorption fine structure

k

photoelectron wave vector

XANES

X-ray absorption near structure

FT

Fourier transform

BS

broken symmetry

COSMO

conductor-like screening model

ε

dielectric constant

Footnotes

ASSOCIATED CONTENT

Supporting Information. Method of sample preparation; Mössbauer spectra of the samples containing X, the reactant complex, and the product of decay of X; XANES spectra of the samples containing X, the reactant complex, and the product complex; XANES and EXAFS spectra of the second scans of samples containing X; additional presentations of fits to the EXAFS data; description of computational methodology and tables with results. This material is available free of charge via the Internet at http://pubs.acs.org

REFERENCES

  • 1.Nordlund P, Reichard P. Annu. Rev. Biochem. 2006;75:681–706. doi: 10.1146/annurev.biochem.75.103004.142443. [DOI] [PubMed] [Google Scholar]
  • 2.Stubbe J. Curr. Opin. Struct. Biol. 2000;10:731–736. doi: 10.1016/s0959-440x(00)00153-6. [DOI] [PubMed] [Google Scholar]
  • 3.Licht S, Gerfen GJ, Stubbe J. Science. 1996;271:477–481. doi: 10.1126/science.271.5248.477. [DOI] [PubMed] [Google Scholar]
  • 4.Stubbe J, Nocera DG, Yee CS, Chang MCY. Chem. Rev. 2003;103:2167–2202. doi: 10.1021/cr020421u. [DOI] [PubMed] [Google Scholar]
  • 5.Stubbe J, Riggs-Gelasco P. Trends Biochem. Sci. 1998;23:438–443. doi: 10.1016/s0968-0004(98)01296-1. [DOI] [PubMed] [Google Scholar]
  • 6.Atkin CL, Thelander L, Reichard P, Lang G. J. Biol. Chem. 1973;248:7464–7472. [PubMed] [Google Scholar]
  • 7.Tong WH, Chen S, Lloyd SG, Edmondson DE, Huynh BH, Stubbe J. J. Am. Chem. Soc. 1996;118:2107–2108. [Google Scholar]
  • 8.Yun D, García-Serres R, Chicalese BM, An YH, Huynh BH, Bollinger JM., Jr Biochemistry. 2007;46:1925–1932. doi: 10.1021/bi061717n. [DOI] [PubMed] [Google Scholar]
  • 9.Bollinger JM, Jr, Krebs C, Vicol A, Chen S, Ley BA, Edmondson DE, Huynh BH. J. Am. Chem. Soc. 1998;120:1094–1095. [Google Scholar]
  • 10.Baldwin J, Krebs C, Ley BA, Edmondson DE, Huynh BH, Bollinger JM., Jr J. Am. Chem. Soc. 2000;122:12195–12206. [Google Scholar]
  • 11.Bollinger JM, Jr, Edmondson DE, Huynh BH, Filley J, Norton JR, Stubbe J. Science. 1991;253:292–298. doi: 10.1126/science.1650033. [DOI] [PubMed] [Google Scholar]
  • 12.Wu CH, Jiang W, Krebs C, Stubbe J. Biochemistry. 2007;46:11577–11588. doi: 10.1021/bi7012454. [DOI] [PubMed] [Google Scholar]
  • 13.Ravi N, Bollinger JM, Jr, Huynh BH, Edmondson DE, Stubbe J. J. Am. Chem. Soc. 1994;116:8007–8014. [Google Scholar]
  • 14.Stubbe J. Curr. Opin. Chem. Biol. 2003;7:183–188. doi: 10.1016/s1367-5931(03)00025-5. [DOI] [PubMed] [Google Scholar]
  • 15.Mitić N, Saleh L, Schenk G, Bollinger JM, Jr, Solomon EI. J. Am. Chem. Soc. 2003;125:11200–11201. doi: 10.1021/ja036556e. [DOI] [PubMed] [Google Scholar]
  • 16.Mitić N, Clay MD, Saleh L, Bollinger JM, Jr, Solomon EI. J. Am. Chem. Soc. 2007;129:9049–9065. doi: 10.1021/ja070909i. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Sturgeon BE, Burdi D, Chen S, Huynh BH, Edmondson DE, Stubbe J, Hoffman BM. J. Am. Chem. Soc. 1996;118:7551–7557. [Google Scholar]
  • 18.Shanmugam M, Doan PE, Lees NS, Stubbe J, Hoffman BM. J. Am. Chem. Soc. 2009;131:3370–3376. doi: 10.1021/ja809223s. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Riggs-Gelasco PJ, Shu L, Chen S, Burdi D, Huynh BH, Que L, Jr, Stubbe J. J. Am. Chem. Soc. 1998;120:849–860. [Google Scholar]
  • 20.Burdi D, Sturgeon BE, Tong WH, Stubbe J, Hoffman BM. J. Am. Chem. Soc. 1996;118:281–282. [Google Scholar]
  • 21.Burdi D, Willems J-P, Riggs-Gelasco P, Antholine WE, Stubbe J, Hoffman BM. J. Am. Chem. Soc. 1998;120:12910–12919. [Google Scholar]
  • 22.Han W-G, Liu T, Lovell T, Noodleman L. J. Am. Chem. Soc. 2005;127:15778–15790. doi: 10.1021/ja050904q. [DOI] [PubMed] [Google Scholar]
  • 23.Han W-G, Liu T, Lovell T, Noodleman L. J. Inorg. Biochem. 2006;100:771–779. doi: 10.1016/j.jinorgbio.2006.01.032. [DOI] [PubMed] [Google Scholar]
  • 24.Han W-G, Liu T, Lovell T, Noodleman L. Inorg. Chem. 2006;45:8533–8542. doi: 10.1021/ic060566+. [DOI] [PubMed] [Google Scholar]
  • 25.Han W-G, Noodleman L. Dalton Trans. 2009:6045–6057. doi: 10.1039/b903847g. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Han W-G, Noodleman L. Theor. Chem. Acc. 2010;125:305–317. doi: 10.1007/s00214-009-0566-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Neese F. J. Biol. Inorg. Chem. 2006;11:702–711. doi: 10.1007/s00775-006-0138-1. [DOI] [PubMed] [Google Scholar]
  • 28.Zang Y, Dong Y, Que L, Jr, Kauffmann K, Münck E. J. Am. Chem. Soc. 1995;117:1169–1170. [Google Scholar]
  • 29.Dong Y, Fujii H, Hendrich MP, Leising RA, Pan G, Randall CR, Wilkinson EC, Zang Y, Que L, Jr, Fox BG, Kauffman K, Münck E. J. Am. Chem. Soc. 1995;117:2778–2792. [Google Scholar]
  • 30.Hsu H-F, Dong Y, Shu L, Young VG, Que L., Jr J. Am. Chem. Soc. 1999;121:5230–5237. [Google Scholar]
  • 31.Younker JM, Krest CM, Jiang W, Krebs C, Bollinger JM, Jr, Green MT. J. Am. Chem. Soc. 2008;130:15022–15027. doi: 10.1021/ja804365e. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Dassama LMK, Yosca TH, Conner DA, Lee MH, Blanc B, Streit BR, Green MT, DuBois JL, Krebs C, Bollinger JM., Jr Biochemistry. 2012;51:1607–1616. doi: 10.1021/bi201906x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Logan DT, Su X-D, Åberg A, Regnström K, Hajdu J, Eklund H, Nordlund P. Structure. 1996;4:1053–1064. doi: 10.1016/s0969-2126(96)00112-8. [DOI] [PubMed] [Google Scholar]
  • 34.Nordlund P, Eklund H. J. Mol. Biol. 1993;232:123–164. doi: 10.1006/jmbi.1993.1374. [DOI] [PubMed] [Google Scholar]
  • 35.Scarrow RC, Maroney MJ, Palmer SM, Que L, Jr, Salowe SP, Stubbe J. J. Am. Chem. Soc. 1986;108:6832–6834. [Google Scholar]
  • 36.Scarrow RC, Maroney MJ, Palmer SM, Que L, Jr, Roe AL, Salowe SP, Stubbe J. J. Am. Chem. Soc. 1987;109:7857–7864. [Google Scholar]
  • 37.Shu L, Nesheim JC, Kauffmann KE, Münck E, Lipscomb JD, Que L., Jr Science. 1997;275:515–518. doi: 10.1126/science.275.5299.515. [DOI] [PubMed] [Google Scholar]
  • 38.Hwang J, Krebs C, Huynh BH, Edmondson DE, Theil EC, Penner-Hahn JE. Science. 2000;287:122–125. doi: 10.1126/science.287.5450.122. [DOI] [PubMed] [Google Scholar]
  • 39.Baldwin J, Krebs C, Saleh L, Stelling M, Huynh BH, Bollinger JM, Jr, Riggs-Gelasco P. Biochemistry. 2003;42:13269–13279. doi: 10.1021/bi035198p. [DOI] [PubMed] [Google Scholar]
  • 40.Gherman BF, Baik M-H, Lippard SJ, Friesner RA. J. Am. Chem. Soc. 2004;126:2978–2990. doi: 10.1021/ja036506+. [DOI] [PubMed] [Google Scholar]
  • 41.Xue G, Wang D, De Hont R, Fiedler AT, Shan X, Münck E, Que L., Jr Proc. Natl. Acad. Sci. U.S.A. 2007;104:20713–20718. doi: 10.1073/pnas.0708516105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Cranswick MA, Meier KK, Shan X, Stubna A, Kaizer J, Mehn MP, Münck E, Que L., Jr Inorg. Chem. 2012;51:10417–10426. doi: 10.1021/ic301642w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Han W-G, Noodleman L. Inorganica Chim Acta. 2008;361:973–986. doi: 10.1016/j.ica.2007.06.007. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1_si_001

RESOURCES